Navigation Links
Nventa Enrolls and Initiates Dosing of Final Cohort in HspE7 Phase 1 Cervical Dysplasia Trial
Date:3/11/2008

r licensing arrangements; our ability to attract and retain key personnel; and other factors as described in detail in our filings with the Canadian securities regulatory authorities at http://www.sedar.com.

Assumptions underlying our expectations regarding forward-looking statements or information contained in this press release include, among others, that we will raise enough capital, on reasonable terms and in a timely manner; that we will retain our key personnel; that we will obtain the necessary regulatory approvals related to HspE7 and our adjuvant in a timely manner; that enough HspE7 will be available to conduct our planned trials; that we will be able to procure the necessary amount of adjuvant to conduct our planned trials; that we will obtain timely approval from additional IRBs; that the results from additional preclinical and clinical work, if any, will be consistent with the results we have already obtained; that a sufficient number of patients will be available to conduct our planned trials; and that sufficient data will be generated to support our IND.

In the event that any of these assumptions prove to be incorrect, or in the event that we are impacted by any of the risks identified above, we may not be able to continue in our business as planned.

For a complete discussion of the assumptions, risks and uncertainties related to our business, you are encouraged to review our filings with Canadian securities regulatory authorities, including our 2006 Annual Information Form filed on SEDAR at http://www.sedar.com. Historical filings relating to the Company prior to the completion of the Company's March 23, 2006 corporate reorganization, including Old Stressgen's 2005 Annual Information Form dated March 16, 2006 may be reviewed on SEDAR at http://www.sedar.com under the SEDAR profile GVIC
'/>"/>

SOURCE Nventa Biopharmaceuticals Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Nventa Evaluation Complete for First Three Cohorts in HspE7 Phase 1 Cervical Dysplasia Trial
2. VIA Pharmaceuticals Enrolls First Patient in Phase 2 Clinical Trial to Measure Impact of VIA-2291 to Reduce Vascular Inflammation
3. Spectranetics Enrolls First Patient in PATENT Trial for the Treatment of Instent Restenosis
4. Ception Therapeutics Initiates Phase II/III Clinical Trial for Its Lead Product Reslizumab in Eosinophilic Esophagitis (EE) in Children
5. Pharmacopeia Initiates Second Phase 2 Hypertension Study with PS433540 (DARA)
6. Phosphagenics Initiates U.S. Clinical Trials for Its Topical Retinoic Acid
7. Alexza Initiates AZ-007 (Staccato(R) Zaleplon) Phase 1 Clinical Trial and Updates Clinical Pipeline Development Status
8. Tigris Pharmaceuticals Initiates Phase I Study of AFP-464 in Patients with Solid Tumors
9. Nuvelo Initiates Phase 1 Clinical Trial of Thrombin Inhibitor, NU172
10. Northwestern Memorial Transplant Program Initiates New Study
11. Cerimon Pharmaceuticals Initiates Phase II/III Clinical Studies to Evaluate its Diclofenac Patch for Mild to Moderate Pain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... 23, 2014 Research and Markets ... "Emulsifiers - Global Strategic Business Report" report ... http://photos.prnewswire.com/prnh/20130307/600769 This report analyzes the ... US$ Thousands by the following Product Segments: Lecithin, ... and Sorbitan Esters, and Polyglycin Polyricinoleate & Others. ...
(Date:7/22/2014)... , July 23, 2014   ... Taiho Pharmaceutical Co., Ltd. (hereinafter "Taiho"), a fully-fledged ... company will be investing US$30 million in Remiges BioPharma ... capital fund. Taiho has a long history ... of oncologists and cancer patients. Our development of TAS-102 ...
(Date:7/22/2014)... July 22, 2014 /PRNewswire-iReach/ -- The global digital ... application, technology, portability, product, end user, price, and ... the highest growth rate in the digital X-ray ... high growth is attributed to technological advancements and ... accounted for the largest share of the digital ...
Breaking Medicine Technology:Emulsifiers - Global Strategic Business Report: Updated 2014 Report 2Emulsifiers - Global Strategic Business Report: Updated 2014 Report 3Taiho Pharmaceutical Invests US$30 Million in Remiges BioPharma Fund, LP 2Global Digital X-Ray Market 2018 Analysis and Forecast In New Research Report Available at RnRMarketResearch.com 2Global Digital X-Ray Market 2018 Analysis and Forecast In New Research Report Available at RnRMarketResearch.com 3Global Digital X-Ray Market 2018 Analysis and Forecast In New Research Report Available at RnRMarketResearch.com 4Global Digital X-Ray Market 2018 Analysis and Forecast In New Research Report Available at RnRMarketResearch.com 5
... the cholera outbreak continues to spread in ... is increasing its response in affected areas, pre-positioning much-needed ... in Port-au-Prince with critical, life-saving health and hygiene messages. ... this will take, we,re preparing for challenging weeks ahead," ...
... -- Sinovac Biotech Ltd. (Nasdaq: SVA ), ... today that it has been selected by the Beijing ... one of the five manufacturers to supply seasonal influenza ... part of the bidding process, the Beijing CDC evaluated ...
Cached Medicine Technology:As Cholera Outbreak Spreads, World Vision Deploys Teams to Distribute Emergency Health Supplies, Focus on Preventative Measures 2Sinovac Selected by Beijing CDC to Supply Seasonal Flu Vaccine Anflu(R) to Beijing Citizens 2Sinovac Selected by Beijing CDC to Supply Seasonal Flu Vaccine Anflu(R) to Beijing Citizens 3
(Date:7/23/2014)... 22, 2014) Mouse models of human oral cancer ... shrinkage without damage to surrounding tissues, researchers from the ... University of Texas Health Science Center at San Antonio ... on results of the study, which is described in ... diagnosis, low survival , Oral squamous cell carcinoma ...
(Date:7/23/2014)... 23, 2014 Follow us ... substances exclusively developed and manufactured for use in ... body tissues. These materials are biosafe with significantly ... Global market for biocompatible materials is expected to ... technological advancements and growing base of aging population ...
(Date:7/23/2014)... July 23, 2014 VogueQueen.com, a reliable ... than ever, hopes to help all clients to get ... online shopping popular in the market. This is why ... business. , Among thousands of online dress suppliers, ... has announced a new collection of fashionable hair ...
(Date:7/23/2014)... Relias Learning, the leader in SaaS-based ... services markets, continued to expand its market presence in ... its core markets and further expansion in new markets. ... SaaS-based training solutions accelerate across a wide range of ... and human services organizations, in particular, are seeing the ...
(Date:7/23/2014)... Fla. (PRWEB) July 23, 2014 FCCI ... Fit-Friendly Worksite by the American Heart Association for helping ... recognized as a Platinum-Level Fit-Friendly Worksite in 2013, 2011, ... 2012. , “FCCI makes employee health and wellness an ... and helping employees stay at the top of their ...
Breaking Medicine News(10 mins):Health News:Anti-pain agent shrinks oral cancers, leaves healthy tissues alone 2Health News:Surge in R&D Investments to Drive the Global Biocompatible Materials Market, According to New Report by Global Industry Analysts, Inc. 2Health News:Surge in R&D Investments to Drive the Global Biocompatible Materials Market, According to New Report by Global Industry Analysts, Inc. 3Health News:Reliable Online Supplier VogueQueen.com Helps Worldwide Ladies To Find Suitable Hair Wigs And Special Occasion Gowns 2Health News:Relias Learning announces Q2 results - continues record growth and new market expansion 2Health News:FCCI Insurance Group Recognized as an American Heart Association Fit-Friendly Worksite 2Health News:FCCI Insurance Group Recognized as an American Heart Association Fit-Friendly Worksite 3
... , SCHAUMBURG, Ill., July 29 ... Agency for Research on Cancer (IARC) for its re-categorization of ... indoor tanning in the highest cancer risk category afforded by ... Health Organization (WHO). , , "The ...
... of serious complications 4.3 percent, , WEDNESDAY, July 29 ... combat significant obesity, a new study suggests the risk ... previously been reported. , The study, which looked at ... (lap-band surgery), found that the risk of death for ...
... American Association for ... ... Cancer Prevention Research , a journal of the American Association for Cancer Research, suggests ... and neck. Furthermore, African Americans had far less HPV infection than whites, which led to ...
... , , ST. LOUIS, July ... second quarter net income from continuing operations of $192.0 million, or ... primarily related to the previously announced acquisition of WellPoint,s pharmacy benefit ... from $0.76 for the same period last year. These earnings for ...
... , , PRINCETON, N.J., July ... today reported GAAP earnings for its second quarter ended June 30, ... share gain related to the sale of its centralized ECG business ... diluted share. , , "On a consolidated basis, ...
... , , SAN DIEGO, July 29 ... company focused on developing products for minimally disruptive surgical treatments for ... and Investor Relations, is scheduled to present at the BMO Capital ... New York, New York, on Wednesday, August 5, 2009, at 11:15 ...
Cached Medicine News:Health News:American Academy of Dermatology Commends Reclassification of Tanning Beds as Carcinogenic 2Health News:American Academy of Dermatology Commends Reclassification of Tanning Beds as Carcinogenic 3Health News:Study Finds Weight-Loss Surgery Safer Than Thought 2Health News:Study Finds Weight-Loss Surgery Safer Than Thought 3Health News:HPV Infection May Be Linked to Poor Head and Neck Cancer Survival Rates in African Americans 2Health News:HPV Infection May Be Linked to Poor Head and Neck Cancer Survival Rates in African Americans 3Health News:HPV Infection May Be Linked to Poor Head and Neck Cancer Survival Rates in African Americans 4Health News:Express Scripts Reports Strong Second Quarter Earnings 2Health News:Express Scripts Reports Strong Second Quarter Earnings 3Health News:Express Scripts Reports Strong Second Quarter Earnings 4Health News:Express Scripts Reports Strong Second Quarter Earnings 5Health News:Express Scripts Reports Strong Second Quarter Earnings 6Health News:Express Scripts Reports Strong Second Quarter Earnings 7Health News:Express Scripts Reports Strong Second Quarter Earnings 8Health News:Express Scripts Reports Strong Second Quarter Earnings 9Health News:Express Scripts Reports Strong Second Quarter Earnings 10Health News:Express Scripts Reports Strong Second Quarter Earnings 11Health News:Express Scripts Reports Strong Second Quarter Earnings 12Health News:Express Scripts Reports Strong Second Quarter Earnings 13Health News:Express Scripts Reports Strong Second Quarter Earnings 14Health News:Covance Reports Second Quarter Revenue of $466M and EPS of $0.66 2Health News:Covance Reports Second Quarter Revenue of $466M and EPS of $0.66 3Health News:Covance Reports Second Quarter Revenue of $466M and EPS of $0.66 4Health News:Covance Reports Second Quarter Revenue of $466M and EPS of $0.66 5Health News:Covance Reports Second Quarter Revenue of $466M and EPS of $0.66 6Health News:Covance Reports Second Quarter Revenue of $466M and EPS of $0.66 7Health News:Covance Reports Second Quarter Revenue of $466M and EPS of $0.66 8Health News:Covance Reports Second Quarter Revenue of $466M and EPS of $0.66 9Health News:Covance Reports Second Quarter Revenue of $466M and EPS of $0.66 10Health News:Covance Reports Second Quarter Revenue of $466M and EPS of $0.66 11Health News:Covance Reports Second Quarter Revenue of $466M and EPS of $0.66 12Health News:Covance Reports Second Quarter Revenue of $466M and EPS of $0.66 13Health News:NuVasive to Present at the BMO Capital Markets 9th Annual Focus on Healthcare Conference 2Health News:NuVasive to Present at the BMO Capital Markets 9th Annual Focus on Healthcare Conference 3
Floor stand stabilizer system...
The robust, easy to maneuver floor-mounted stepper/stabilizer, offers strength and stability that has made this unit one of the most widely accepted floor fixation devices in the industry....
... of a welded titanium capsule containing either ... beads. The capsule body also contains ... x-ray markers to identify the source location ... non-sterile when shipped and must be sterilized ...
A Powerful New Quantitative Immunoassay for Monitoring Bladder Cancer Patients. Useful in Monitoring Patients for,Disease Progression and Recurrence....
Medicine Products: